Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Renal Insufficiency × melflufen × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 5 Renal Insufficiency 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Dexamethasone 13 Bortezomib 8 Cyclophosphamide 5 Lenalidomide 4 pomalidomide 3 isatuximab 3 Calcium Dobesilate 3 Thalidomide 2 Kidney Transplantation 2 melflufen 1 dexamethasone acetate 1 dexamethasone 21-phosphate 1 daratumumab 1 carfilzomib 1 belantamab mafodotin 1 auricularum 1 Whole-Body Irradiation 1 Tablets 1 Ranitidine 1 Plasmapheresis 1 L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1 Drug Therapy 1 Doxorubicin 1 Diphenhydramine 1 Data Collection 1 Cyclosporine 1 Bendamustine Hydrochloride 1 BHQ880 1 Azacitidine 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03639610 2023-03-10

BRIDGE

Oncopeptides AB

Phase 2 Terminated

35 enrolled 33 charts

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon ⚡